CASI Pharmaceuticals shares plummeted 64% to an all-time low after Nasdaq decided to delist the company for failing to meet listing requirements. Trading will be suspended on Thursday, and CASI does not plan to appeal. The company expects its shares to move to the over-the-counter market following the removal from Nasdaq.